SG Americas Securities LLC bought
57,553 shares of
Laboratory Corporation of America Holdings. The firm announced its
Q1 2024 results and future earnings call dates. It looks to increase
mPox testing capacity and received regulatory approval for a diagnostic used with
Pfizer’s hemophilia B gene therapy. However, certain shares were sold by
Squarepoint Ops LLC.
Labcorp made a successful bid for select assets of
Invitae and also acquired assets from
BioReference Health's Diagnostics. The firm showed steady growth, outperforming Q2 profit and revenue estimates. They issued new senior notes and received new investments from
MBB Public Markets I. They announced a quarterly dividend and various analysts issued ratings on the company. They inked a new deal to boost clinical diagnostics, they presented at an annual growth stock conference and collaborated with
Hawthorne Effect to bring clinical trials to local communities. Though there were a few negative pointers such as a lowered price target and shares sold by different asset management companies. They introduced a new test to assess preeclampsia risk and presented new research for patients with epithelial ovarian cancer.
Laboratory Corporation of America Holdings LH News Analytics from Mon, 24 Oct 2016 07:00:00 GMT to Sat, 05 Oct 2024 14:23:21 GMT -
Rating 6
- Innovation 2
- Information 8
- Rumor -2
